PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions

Footnotes and References

1.Buch AB, Van Harken DR, Seidehamel RJ, Barbhaiya RH. A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. Journal of Clinical Pharmacology 1993; 33: 1104-09.[PubMed]
2.Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, Funck-Brentano C. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clinical Pharmacology & Therapeutics 2007; 81: 679-84.[PubMed]
3.Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clinical Pharmacology & Therapeutics 2003; 73: 264-71.[PubMed]
4.Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittel-Forschung/Drug Research 1996; 46: 213-17.[PubMed]
5.Cockshott ID. Bicalutamide - Clinical pharmacokinetics and metabolism. Clinical Pharmacokinetics 2004; 43: 855-78.[PubMed]
6.Somogyi A, Muirhead M. Pharmacokinetic Interactions of Cimetidine 1987. Clinical Pharmacokinetics 1987; 12: 321-66.[PubMed]
7.Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 47-53.[PubMed]
8.Li G, Treiber G, Meinshausen J, Wolf J, Werringloer J, Klotz U. Is cyclosporin A an inhibitor of drug metabolism? British Journal of Clinical Pharmacology 1990; 30: 71-77.[PubMed]
9.Lam YWF, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. Journal of Clinical Pharmacology 2003; 43: 1274-82.[PubMed]
10.Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. British Journal of Clinical Pharmacology 1983; 16: 743-46.[PubMed]
11.Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65: 19-26.[PubMed]
12.Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1 '-hydroxylation. British Journal of Clinical Pharmacology 2000; 50: 333-37.[PubMed]
13.Elliott P, Dundee JW, Elwood RJ, Collier PS. The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam. European Journal of Anaesthesiology 1984; 1: 245-51.[PubMed]
14.Backman JT, Aranko K, Himberg JJ, Olkkola KT. A pharmacokinetic interaction between roxithromycin and midazolam. European Journal of Clinical Pharmacology 1994; 46: 551-55.[PubMed]
15.Prueksaritanont T, Vega JM, Zhao J, Gagliano K, Kuznetsova O, Musser B, Amin RD, Liu L, Roadcap BA, Dilzer S, Lasseter KC, Rogers JD. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. Journal of Clinical Pharmacology 2001; 41: 573-81.[PubMed]
Disclaimer
WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.